Search Within

Martin Stuart Tallman

  1. "2015"
Formats
  1. Meeting Abstract (38)
  2. Journal Article (25)
  3. Book Section (1)
Groups
  1. Adult Leukemia (64)
  2. Center for Hematologic Malignancies (64)
  3. Department of Medicine (64)
  4. Hematologic Malignancies, Division of (64)
  5. Executive Committee, Center for Hematologic Malignancies (21)
  6. GSK Faculty (21)

More Groups

People
  1. Ross Levine (18)
  2. Eytan Stein (10)
  3. Omar Abdel-Wahab (8)
  4. Sean Devlin (7)
  5. Dan Douer (6)
  6. Jae Park (6)

More People

Years
  1. 2015 (64)
Publications
  1. Blood (30)
  2. Clinical Lymphoma, Myeloma and Leukemia (5)
  3. Journal of Clinical Oncology (4)
  4. Haematologica (3)
  5. Leukemia (3)
  6. Biology of Blood and Marrow Transplantation (2)

More Publications

Publishers
  1. American Society of Hematology (30)
  2. Elsevier Inc. (8)
  3. Nature Publishing Group (5)
  4. American Society of Clinical Oncology (4)
  5. Ferrata Storti Foundation (3)
  6. John Wiley & Sons (2)

More Publishers

Results (64)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Predictors of early death in childhood acute promyelocytic leukemia: Results of an international retrospective study
    Meeting Abstract

    Abla, O.; Ribeiro, R. C.; Testi, A. M.; Fernandez, P. M.; Creutzig, U.; Sung, L. L.; Di Giuseppe, G.; Stephens, D.; Hasle, H.; Kaspers, G. J. L.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • DH2 inhibitors in acute myeloid leukemia
    Meeting Abstract

    Coombs, C. C.; Stein, E. M.; Levine, R. L.; Tallman, M. S.
    Annals of Hematology (2015)

    Fulltext@MSK | Save
  • Cost-effectiveness analysis of treating acute promyelocytic leukemia patients with arsenic trioxide and retinoic acid in the United States
    Journal Article

    Tallman, M.; Lo-Coco, F.; Barnes, G.; Kruse, M.; Wildner, R.; Martin, M.; Mueller, U.; Tang, B.
    Clinical Lymphoma, Myeloma and Leukemia (2015)

    Fulltext@MSK | Save
  • Hairy cell leukemia: Past, present and future
    Journal Article

    Getta, B. M.; Park, J. H.; Tallman, M. S.
    Best Practice and Research: Clinical Haematology (2015)

    Fulltext@MSK | Save
  • Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias
    Journal Article

    Kucine, N.; Marubayashi, S.; Bhagwat, N.; Papalexi, E.; Koppikar, P.; Martin, M. S.; Dong, L.; Tallman, M. S.; Paietta, E.; Wang, K.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • High ΔNp73/TAp73 ratio is associated with poor prognosis in acute promyelocytic leukemia
    Journal Article

    Lucena-Araujo, A. R.; Kim, H. T.; Thomé, C.; Jacomo, R. H.; Melo, R. A.; Bittencourt, R.; Pasquini, R.; Pagnano, K.; Glória, A. B. F.; de Lourdes Chauffaille, M.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia
    Journal Article

    Tiacci, E.; Park, J. H.; De Carolis, L.; Chung, S. S.; Broccoli, A.; Scott, S.; Zaja, F.; Devlin, S.; Pulsoni, A.; Chung, Y. R.; more...
    New England Journal of Medicine (2015)

    Fulltext@MSK | Save
  • Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: A long-term follow-up study of the US intergroup phase III trial E2997
    Journal Article

    Lucas, D. M.; Ruppert, A. S.; Lozanski, G.; Dewald, G. W.; Lozanski, A.; Claus, R.; Plass, C.; Flinn, I. W.; Neuberg, D. S.; Paietta, E. M.; more...
    Leukemia and Lymphoma (2015)

    Fulltext@MSK | Save
  • Ag-221, an oral, selective, first-in-class, potent inhibitor of the IDH2 mutant enzyme, induced durable responses in a phase 1 study of IDH2 mutation-positive advanced hematologic malignancies
    Meeting Abstract

    DiNardo, C.; Stein, E. M.; Altman, J. K.; Collins, R.; DeAngelo, D. J.; Fathi, A. T.; Flinn, I.; Frankel, A.; Levine, R. L.; Medeiros, B. C.; more...
    Haematologica (2015)

    Fulltext@MSK | Save
  • Clinical safety and activity of AG-120, a first-in-class, potent inhibitor of the IDH1 mutant protein, in a phase 1 study of patients with advanced IDH1-mutant hematologic malignancies
    Meeting Abstract

    de Botton, S.; Pollyea, D. A.; Stein, E. M.; DiNardo, C.; Fathi, A. T.; Roboz, G. J.; Collins, R.; Swords, R. T.; Flinn, I.; Altman, J. K.; more...
    Haematologica (2015)

    Fulltext@MSK | Save